Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.
Heidi Overton, nominated to lead the FDA, faced intense scrutiny over her stances on vaccines, birth control, and vaping products. Her evasive responses have reignited debates about the influence of former President Trump on public health policy.
Kratom, a herbal substance linked to the tragic deaths of two college students, is drawing increasing scrutiny from U.S. officials. As its popularity surges, concerns about its safety and regulation intensify.
Heidi Overton, President Donald Trump's pick to lead the Food and Drug Administration, faced pointed questioning over vaccines, birth control and vaping during her confirmation hearing. The exchange underscored how closely the agency's future could be tied to political loyalty as much as scientific judgment. Overton declined to say whether Trump can ever be wrong, a moment that sharpened concerns among lawmakers and public health observers about the independence of the nation's top drug regulator.
Indian pharma’s biggest listed manufacturers are being pulled in opposite directions: toward higher-value biologics, complex injectables and biosimilars, and back toward the basics of manufacturing discipline under intensifying USFDA scrutiny. For Sun Pharma, Dr. Reddy’s and Cipla, the strategic prize is clear—less commoditised growth, better margins and a stronger moat against price erosion in the US generics market. But the regulatory cost of failure is rising, with Form 483 observations, warning letters and import-risk disruptions forcing expensive remediation and slowing launches. The deeper challenge is structural. India’s generic champions still depend on the US for a large share of profits while relying on China for critical APIs and intermediates. That leaves them exposed to two forms of concentration risk at once: compliance concentration in FDA-inspected plants and supply-chain concentration in upstream chemistry. The companies are now spending billions of rupees to diversify APIs, automate plants and build biologics platforms, but the transition is uneven, capital-intensive and vulnerable to any fresh USFDA setback.
Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.
Entities frequently referenced alongside US FDA: